diclofenac

diclofenac
Drug name	Diclofenac
Tradename	Voltaren, Cataflam, Solaraze, others
Routes of administration	Oral; topical; rectal; intramuscular; intravenous; ophthalmic

diclofenac is a nonsteroidal anti-inflammatory drug used to treat pain, inflammation, and fever. It is commonly prescribed for acute musculoskeletal injuries, postoperative pain, and chronic conditions such as osteoarthritis and rheumatoid arthritis. Major manufacturers and regulatory agencies have overseen its development, approval, and postmarketing surveillance.

Medical uses

Diclofenac is indicated for management of acute pain, chronic inflammatory disorders, and dysmenorrhea, and is used in postoperative settings and topical therapy for localized musculoskeletal conditions. Typical clinical contexts include treatment of Osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis, and acute soft tissue injuries; it is also used in ophthalmology for postoperative inflammation after procedures such as Cataract surgery and for topical dermatologic indications like actinic keratosis. Pain management protocols in settings such as Orthopedic surgery, Dental extraction and Cesarean section frequently include diclofenac as part of multimodal analgesia guided by institutions including the World Health Organization and national health agencies.

Mechanism of action

Diclofenac exerts anti-inflammatory, analgesic, and antipyretic effects primarily via inhibition of cyclooxygenase enzymes, affecting prostaglandin synthesis. It is a nonselective but somewhat COX-2–preferential inhibitor that reduces levels of prostaglandin E2 and other mediators implicated in inflammatory pathways relevant to conditions treated in Rheumatology and Pain management. Secondary pharmacologic actions include modulation of intracellular signaling and effects on leukocyte function reported in studies from academic centers such as Johns Hopkins University and University of California, San Francisco.

Pharmacokinetics

Diclofenac demonstrates rapid absorption after oral administration with significant first-pass hepatic metabolism predominantly via cytochrome P450 enzymes, including CYP2C9 and CYP3A4. Plasma protein binding is high, affecting distribution to tissues implicated in disorders treated at facilities like Mayo Clinic and Cleveland Clinic. Metabolites are excreted in urine and bile; elimination half-life and steady-state kinetics inform dosing schedules recommended by regulatory bodies such as the European Medicines Agency and the U.S. Food and Drug Administration.

Adverse effects and contraindications

Adverse effects include gastrointestinal mucosal injury, renal impairment, cardiovascular risk elevation, hepatic dysfunction, hypersensitivity reactions, and dermatologic events. Serious complications reported in literature and regulatory warnings involve gastrointestinal bleeding in contexts referenced by studies at Harvard Medical School and increased risk of myocardial infarction and stroke discussed in guidance from the European Commission and the U.S. FDA. Contraindications include known hypersensitivity, history of aspirin-exacerbated respiratory disease such as Aspirin-intolerant asthma, and active peptic ulcer disease; caution is advised in patients with congestive heart failure managed at centers like Mount Sinai Hospital.

Formulations and administration

Diclofenac is available in immediate-release and sustained-release oral tablets, topical gels and patches, rectal suppositories, intramuscular and intravenous injectables, and ophthalmic drops. Topical formulations are commonly used for localized musculoskeletal pain in outpatient settings such as Kaiser Permanente clinics, while injectable forms are employed in perioperative care in institutions including Massachusetts General Hospital. Formulation choice is influenced by clinical setting, patient comorbidities, and regulatory labeling from agencies like Health Canada.

Drug interactions

Diclofenac interacts with anticoagulants, antiplatelet agents, other nonsteroidal anti-inflammatory drugs, antihypertensive agents including angiotensin-converting enzyme inhibitors and diuretics, and drugs metabolized by CYP2C9 and CYP3A4. Concomitant use with agents such as Warfarin or Clopidogrel increases bleeding risk; interactions with Methotrexate and Lithium can affect toxicity profiles. Clinicians refer to formularies and interaction databases maintained by organizations like British National Formulary and hospital pharmacy programs at Johns Hopkins Hospital.

History and regulatory status

Diclofenac was developed in the 1960s–1970s and introduced into clinical use in the late 20th century, with major pharmaceutical companies obtaining marketing approvals across Europe, North America, and other regions. Postmarketing surveillance by agencies including the U.S. Food and Drug Administration, the European Medicines Agency, and national regulators prompted label updates regarding cardiovascular and gastrointestinal risks and restrictions in veterinary contexts following environmental impact findings involving vulture populations in South Asia investigated by conservation groups such as World Wildlife Fund and researchers at institutions like University of Cambridge. Contemporary regulatory actions vary by country, with periodic reassessment by health authorities in response to emerging safety and environmental data.

Category:Nonsteroidal anti-inflammatory drugs